ImmunityBio

ImmunityBio is a clinical-stage biotechnology company focused on developing innovative treatments and vaccines for cancer and infectious diseases. The company utilizes its expertise in immunology and cell biology to create therapies that target the root causes of diseases. ImmunityBio's mission is to harness the power of the immune system to prevent and treat diseases. With its cutting-edge research and development, the company aims to make a significant impact on global health.

Company overview

ImmunityBio is headquartered in San Diego, California, and was founded by a team of experienced scientists and entrepreneurs, including Dr. Luis N. Rodriguez, Dr. Siobhan M. Holbeck, and Dr. Asha Patel. The company has established a strong presence in the biotech industry, collaborating with top research institutions and pharmaceutical companies. ImmunityBio's research and development efforts are focused on creating novel therapies that leverage the body's natural immune response to fight disease.

Technology and platforms

ImmunityBio's technology platforms are centered around its proprietary hAd5 adenoviral vector, which is used to deliver genetic material to cells. This platform enables the development of vaccines and therapies for a range of diseases, including cancer, HIV, and tuberculosis. The company's IL-15 superagonist, N-803, has shown promise in clinical trials for its ability to stimulate the immune system and induce anti-tumor responses. ImmunityBio's technology has also been applied to the development of COVID-19 vaccines and treatments.

Clinical development and pipeline

ImmunityBio has a robust pipeline of clinical-stage programs, including several Phase I, Phase II, and Phase III trials. The company's lead candidate, N-803, is being evaluated in multiple clinical trials for its safety and efficacy in treating various types of cancer, including melanoma, lung cancer, and breast cancer. ImmunityBio is also conducting clinical trials for its HIV vaccine candidate, which has shown promising results in early-stage studies. The company is working closely with regulatory agencies, including the US Food and Drug Administration (FDA), to advance its programs through the development process.

Corporate history and leadership

ImmunityBio was founded in 2016 by a team of experienced biotech entrepreneurs and scientists. The company's leadership team includes Dr. Luis N. Rodriguez, CEO, and Dr. Siobhan M. Holbeck, CSO. ImmunityBio has established partnerships with several top research institutions, including the National Institutes of Health (NIH), to support its research and development efforts. The company has also received funding from prominent investors, including F-Prime Capital and Johnson & Johnson.

Partnerships and collaborations

ImmunityBio has established collaborations with several leading pharmaceutical companies, including Johnson & Johnson, Pfizer, and Merck & Co. These partnerships have enabled the company to leverage its technology platforms and accelerate the development of its clinical-stage programs. ImmunityBio has also partnered with research institutions, including the University of California, San Diego and the University of Washington, to advance its research and development efforts. The company's partnerships have helped to establish it as a leader in the biotech industry and have facilitated the development of innovative treatments and vaccines.

Category:Biotechnology companies